Synthesis and preliminary evaluation of n.c.a. iodoquine: A novel radiotracer with high uptake in cells with high aldh1 expression

Current Radiopharmaceuticals

Volumn 5, Issue 1, 2012, Pages 47-58

  Chin, Bennett B ^a   Hjelemand, Anita ^b   Rich, Jeremy ^b   Song, Haijing ^a   Lascola, Christopher ^a   Storms, Robert ^a   Mclendon, Roger ^a   Reiman, Robert ^a   Greer, Kim L ^a   Metzler, Scott D ^c   McDougald, Darryl ^a   Dai, Diana ^a   Vaidyanathan, Ganesan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer stem cells; Iodoquine; Micro spect; Radionuclide imaging; Stem cells

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A1; CD133 ANTIGEN; CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; IODINE 123; IODINE 125; IODINE 131; IODOQUINE; IODOQUINE I 123; IODOQUINE I 125; IODOQUINE I 131; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ASSAY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOSIMETRY; DRUG SCREENING; ELECTROENCEPHALOGRAM; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA L 1210; LUNG CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE DISTRIBUTION; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; URINARY EXCRETION;

ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHLOROQUINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOBLASTOMA; IODINE RADIOISOTOPES; ISOENZYMES; LEUKEMIA L1210; MALE; MICE; MICE, NUDE; NEOPLASMS; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RETINAL DEHYDROGENASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 83455212244     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011205010047     Document Type: Article

References (34)

1. Reya, T.; Morrison, S. J.; Clarke, M. F.; and Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414, 105-111.
2. Pardal, R.; Clarke, M. F.; and Morrison, S. J. Applying the principles of stem-cell biology to cancer. Nature Reviews Cancer, 2003, 3, 895-902.
3. Al Hajj, M. and Clarke, M. F. Self-renewal and solid tumor stem cells. Oncogene, 2004, 23, 7274-7282.
4. Dalerba, P.; Cho, R. W.; and Clarke, M. F. Cancer stem cells: Models and concepts. Annual Review of Medicine, 2007, 58, 267-284.
5. Jones, R. J. and Matsui, W. Cancer stem cells: From bench to bedside. Biology of Blood and Marrow Transplantation, 2007, 13, 47-52.
6. Miyamoto, T.; Weissman, I. L.; and Akashi, K. AML1/ETOexpressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc.Natl.Acad.Sci.U.S.A. 2000, 1997, 7521-7526.
7. Al Hajj, M.; Wicha, M. S.; Benito-Hernandez, A.; Morrison, S. J.; and Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3983-3988.
8. Hendrix, M. J. C.; Seftor, E. A.; Seftor, R. E. B.; Kasemeier- Kulesa, J.; Kulesa, P. M.; and Postovit, L. M. Reprogramming metastatic tumour cells with embryonic microenvironments. Nature Reviews Cancer, 2007, 7, 246-255.
9. Lou, H. and Dean, M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene, 2007, 26, 1357-1360.
10. Bao, S. D.; Wu, Q. L.; McLendon, R. E.; Hao, Y. L.; Shi, Q.; Hjelmeland, A. B.; Dewhirst, M. W.; Bigner, D. D.; and Rich, J. N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444, 756-760.
11. Singh, S. K.; Hawkins, C.; Clarke, I. D.; Squire, J. A.; Bayani, J.; Hide, T.; Henkelman, R. M.; Cusimano, M. D.; and Dirks, P. B. Identification of human brain tumour initiating cells. Nature, 2004, 432, 396-401.
12. Park, C. Y.; Tseng, D.; and Weissman, I. L. Cancer Stem Cell- Directed Therapies: Recent Data From the Laboratory and Clinic. Molecular Therapy, 2009, 17, 219-230.
13. Storms, R. W.; Green, P. D.; Safford, K. M.; Niedzwiecki, D.; Cogle, C. R.; Colvin, O. M.; Chao, N. J.; Rice, H. E.; and Smith, C. A. Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood, 2005, 106, 95-102.
14. Storms, R. W.; Safford, K.; Colvin, O. M.; Rice, H.; and Smith, C. A. CD34+cells that express aldehyde dehydrogenase are primitive hematopoietic progenitors. Blood, 2002, 100, 154B-154B.
15. Storms, R. W.; Trujillo, A. P.; Springer, J. B.; Shah, L.; Colvin, O. M.; Ludeman, S. M.; and Smith, C. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9118-9123.
16. Moreb, J.; Zucali, J. R.; Zhang, Y.; Colvin, M. O.; and Gross, M. A. Role of Aldehyde Dehydrogenase in the Protection of Hematopoietic Progenitor Cells from 4-Hydroperoxycyclophosphamide by Interleukin-1-Beta and Tumor-Necrosis-Factor. Cancer Research, 1992, 52, 1770-1774.
17. Radin, A. I.; Zhoa, X. L.; Woo, T. H.; Colvin, O. M.; and Hilton, J. Structure and Expression of the Cytosolic Aldehyde Dehydrogenase Gene in Cyclophosphamide-Resistant Murine Leukemia L1210-Cells. Biochemical Pharmacology, 1991, 42, 1933-1939.
18. Friedman, H. S.; Colvin, O. M.; Kaufmann, S. H.; Ludeman, S. M.; Bullock, N.; Bigner, D. D.; and Griffith, O. W. Cyclophosphamide Resistance in Medulloblastoma. Cancer Research, 1992, 52, 5373-5378.
19. Quemener, V.; Moulinoux, J. P.; Martin, C.; Darcel, F.; Guegan, Y.; Faivre, J.; and Quash, G. A. Aldehyde Dehydrogenase-Activity in Xenografted Human Brain-Tumor in Nude-Mice - Preliminary- Results in Human Glioma Biopsies. Journal of Neuro-Oncology, 1990, 9, 115-123.
20. Ginestier, C.; Hur, M. H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C. G.; Liu, S. L.; Schott, A.; Hayes, D.; Birnbaum, D.; Wicha, M. S.; and Dontu, G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 2007, 1, 555-567.
21. Huang, E. H.; Hynes, Mark J.; Zhang, Tao; Ginestier, Christophe; Dontu, Gabriela; Appelman, Henry; Fields, Jeremy Z.; Wicha, Max S.; and Boman, Bruce M. Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis. Cancer Research, 2009, 69, 3382-3389.
22. Graves, P. R.; Kwiek, J. J.; Fadden, P.; Ray, R.; Hardeman, K.; Coley, A. M.; Foley, M.; and Haystead, T. A. J. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Molecular Pharmacology, 2002, 62, 1364-1372.
23. Amaravadi, R. K.; Yu, D. N.; Lum, J. J.; Bui, T.; Christophorou, M. A.; Evan, G. I.; Thomas-Tikhonenko, A.; and Thompson, C. B. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. Journal of Clinical Investigation, 2007, 117, 326-336.
24. Holtzman, E. Lysosomes. 1989, 1, 93-99.
25. + exchanger in metastasis. Nature Reviews Cancer, 2005, 5, 786-795.
26. Castino, R.; Demoz, M.; and Isidoro, C. Destination 'Lysosome': a target organelle for tumour cell killing? Journal of Molecular Recognition, 2003, 16, 337-348.
27. Vezmar, M. and Georges, E. Direct binding of chloroquine to the multidrug resistance protein (MRP) - Possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochemical Pharmacology, 1998, 56, 733-742.
28. Vezmar, M. and Georges, E. Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochemical Pharmacology, 2000, 59, 1245-1252.
29. Projean, D.; Baune, B.; Farinotti, R.; Flinois, J. P.; Beaune, P.; Taburet, A. M.; and Ducharme, J. In vitro metabolism of chloroquine: Identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metabolism and Disposition, 2003, 31, 748-754.
30. De, D. Y. D.; Krogstad, F. M.; Byers, L. D.; and Krogstad, D. J. Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines. Journal of Medicinal Chemistry, 1998, 41, 4918-4926.
31. Metzler, S. D.; Jaszczak, R. J.; Patil, N. H.; Vemulapalli, S.; Akabani, G.; and Chin, B. B. Molecular imaging of small animals with a triple-head SPECT system using pinhole collimation. IEEE Transactions on Medical Imaging, 2005, 24, 853-862.
32. Vemulapalli, S.; Metzler, S. D.; Akabani, G.; Petry, N. A.; Niehaus, N. J.; Liu, X.; Patil, N. H.; Greer, K. L.; Jaszczak, R. J.; Coleman, R. E.; Dong, C.; Goldschmidt-Clermont, P. J.; and Chin, B. B. Cell therapy in murine atherosclerosis: in vivo imaging with highresolution helical SPECT. Radiology, 2007, 242, 198-207.
33. Bakker, C. N. M. and Kaspersen, F. M. Labeling of 4-Alkylamino- Iodoquinolines with Radioactive Iodine by Isotopic Exchange. Journal of Labelled Compounds & Radiopharmaceuticals, 1979, 16, 917-928.
34. Vanlangevelde, A.; Bakker, C. N. M.; Boer, H.; Ilmer, T. A. M.; Journeedekorver, J. A.; Kaspersen, F. M.; Noach, E. L.; Oosterhuis, J. A.; and Pauwels, E. K. J. Potential Radiopharmaceuticals for the Detection of Ocular Melanoma. 2. Iodoquinoline Derivatives and Citrate-Ga-67. European Journal of Nuclear Medicine, 1986, 12, 96-104.